Alimera Sciences

Retinal Disease
is Our Focus

Moving the back of the eye to the forefront
of research and development.

Learn more about our goals »

ILUVIEN: Investigational Treatment for DME

ILUVIEN® Fluocinolone acetonide intravitreal insert .019 mg

ILUVIEN® has received its marketing authorization approval in Austria, France, Germany, Portugal, Spain and the United Kingdom and is going through the national phase in the approval process in Italy. Alimera Sciences is still seeking approval in the United States.

Learn more >

Diabetes is the leading cause of new cases of blindness in adults

DIABETES and
VISION LOSS

Diabetes is the leading cause of new cases of blindness in adults.

Learn More >

Latest News

View All Recent News »

Alimera Sciences To Release Second Quarter 2014 Results

July 24, 2014 --  Alimera Sciences, Inc. (NASDAQ: ALIM), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its second quarter of fiscal...

Read More »

Alimera Sciences' ILUVIEN® Receives Positive Outcome Of Repeat-Use Procedure For 10 Additional European Countries

June 30, 2014 --  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the positive outcome of the Repeat-Use Procedure for...

Read More »

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Italy For The Treatment Of Chronic Diabetic Macular Edema

June 23, 2014 --  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Italian Medicines Agency (Agenzia Italiana del...

Read More »